Drug Profile
Celecoxib/famciclovir - Virios Therapeutics
Alternative Names: Famciclovir/celecoxib; IMC-1Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Innovative Med Concepts
- Developer Virios Therapeutics
- Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Antivirals; Irritable bowel syndrome therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Nucleosides; Purines; Pyrazoles; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; DNA-directed DNA polymerase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Fibromyalgia
- Phase I Chronic fatigue syndrome; Irritable bowel syndrome
Most Recent Events
- 04 Mar 2024 Celecoxib/famciclovir - Virios Therapeutics is available for licensing as of 29 Feb 2024. https://www.virios.com/#comp-ig277xvm1
- 09 Aug 2023 Virios Therapeutics plans to submit its final phase III program outline and associated study protocols to the US FDA for review
- 09 Aug 2023 Virios Therapeutics plans a pharmacokinetic clinical trial in Healthy volunteers in USA (PO), in 2023